Market closedNon-fractional

Corvus Pharmaceuticals/CRVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Ticker

CRVS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Burlingame, United States

Employees

28

CRVS Metrics

BasicAdvanced
$114M
Market cap
-
P/E ratio
-$0.51
EPS
1.05
Beta
-
Dividend rate
$114M
1.05
3.4
3.301
3.117
3.117
-29.33%
-60.46%
2.66
2.66
-4.22
-41.99%
50.18%

What the Analysts think about CRVS

Analyst Ratings

Majority rating from 4 analysts.
Buy

CRVS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.7M
-13.64%
Profit margin
0.00%
NaN%

CRVS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.12
-$0.14
-$0.12
-
Expected
-$0.14
-$0.12
-$0.12
-$0.14
-$0.11
Surprise
0.54%
-1.64%
17.65%
-11.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Corvus Pharmaceuticals stock?

Corvus Pharmaceuticals (CRVS) has a market cap of $114M as of July 06, 2024.

What is the P/E ratio for Corvus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of July 06, 2024.

Does Corvus Pharmaceuticals stock pay dividends?

No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Corvus Pharmaceuticals dividend payment date?

Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Corvus Pharmaceuticals?

Corvus Pharmaceuticals (CRVS) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Corvus Pharmaceuticals stock

Buy or sell Corvus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing